Clinical trials: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Condition Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Funder type Industry (pharma, biotech, devices)
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study.
- Trial name
- NCT02955355
- Testing
- HYQVIA
- Where
- 35 sites in United States, Argentina and 16 more
- Volunteers
- 85 people
- Sponsor
- Baxalta now part of Shire
Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome
RWE-based Treatment Patterns and Outcomes in CIDP
To describe the demographics, clinical characteristics, treatment patterns and clinical outcomes of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), and heredofamilial amyloidosis (hATTR)…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hereditary Amyloidosis
- Trial name
- NCT05940922
- Testing
- No intervention. Retrospective observation only.
- Where
- United Kingdom
- Volunteers
- 170 people
- Sponsor
- RwHealth
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
Vitaccess Real CIDP Registry
Vitaccess Real CIDP (VRCIDP) is a patient registry designed to capture longitudinal observational data on chronic inflammatory demyelinating polyneuropathy (CIDP), its treatment, and impact on symptoms, daily activities, and…
- Trial name
- VRCIDP (NCT07006597)
- Volunteers
- 300 people
- Sponsor
- Vitaccess Ltd
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
- Trial name
- NCT05014724
- Testing
- Rozanolixizumab
- Sponsor
- UCB Biopharma SRL
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP.
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Trial name
- emlight (NCT07638566)
- Testing
- Empasiprubart IV
- Volunteers
- 6 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
The single-center, open-label Phase II study has the objective of assess the effect of MD1003 on motor and sensory conduction in patients suffering from demyelinating polyneuropathies in 15 subjects.
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy, Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth Disease Type 1A
- Trial name
- NCT02967679
- Testing
- MD1003
- Where
- France
- Volunteers
- 15 people
- Sponsor
- MedDay Pharmaceuticals SA
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Trial name
- ADHERE (NCT04281472)
- Testing
- efgartigimod PH20 SC in stage B
- Where
- 216 sites in United States, Austria and 23 more
- Volunteers
- 322 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.
- Trial name
- PRISM (NCT02293460)
- Testing
- I10E
- Where
- 33 sites in France, Italy and 4 more
- Volunteers
- 44 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people…
- Trial name
- XPERT (NCT07540221)
- Testing
- Gamunex-C, Xembify
- Where
- 15 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Chronic Inflammatory Demyelinating Polyneuropathy
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is an open-label extension (OLE) study designed to evaluate the long-term safety and tolerability of batoclimab in participants with CIDP who have completed Study IMVT-1401-2401 (NCT05581199).
- Trial name
- NCT07188844
- Testing
- Batoclimab
- Where
- 30 sites in United States, Argentina and 9 more
- Volunteers
- 26 people
- Sponsor
- Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)…
- Trial name
- NCT06752356
- Testing
- Immune globulin (human) 10% solution for intravenous administration
- Where
- 6 sites in United States
- Volunteers
- 161 people
- Sponsor
- Kedrion S.p.A.
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg.
- Trial name
- VITALIZE (NCT06290141)
- Testing
- riliprubart, IVIg
- Where
- 134 sites in United States, Argentina and 22 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
- Trial name
- ADHERE+ (NCT04280718)
- Testing
- Efgartigimod PH20 SC
- Where
- 147 sites in United States, Austria and 22 more
- Volunteers
- 229 people
- Sponsor
- argenx
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care.
- Trial name
- MOBILIZE (NCT06290128)
- Testing
- Riliprubart
- Where
- 132 sites in United States, Argentina and 22 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Polyneuropathy, Inflammatory Demyelinating, Chronic
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual…
- Trial name
- ORBIT-CIDP (NCT06968975)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sanofi
Chronic Inflammatory Demyelinating Polyneuropathy
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP.
- Trial name
- NCT05581199
- Testing
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 94 people
- Sponsor
- Immunovant Sciences GmbH
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Trial name
- emvigorate (NCT06920004)
- Testing
- empasiprubart, IVIg
- Where
- 107 sites in United States, Argentina and 29 more
- Volunteers
- 218 people
- Sponsor
- argenx